The effect of add on omalizumab therapy for two years, on current asthma control, and future exacerbations were evaluated in severe allergic and non-allergic asthma patients treated with high doses inhaled steroids and long acting beta agonist combinations.37 allergic asthma and 8 non-allergic asthma patients receiving omalizumab theraphy during last two years were included to the study. Initial, first, second years ACT, FEV1 and exacerbations treated with a minimum 3 day systemic steroids were calculated. The difference between two groups were analyzed with Portable SPSS.Mean age of omalizumab group of 26 women and 11 males was 41,9±11,7 years. Mean age of control group of 5 women and 3 male was 59,5±14,8 years (p<0,05).All two groups had statistically meaningful increase in their ACT level for the first and second years (p<0,05). At the second year 89,4% decrease of exacerbations for allergic astham group, 72,5% decrease of exacerbations for non-allergic group regarding initial rate were calculated. FEV1 ve FEV1% initial and during 2 years were not statistically different between two groups (p>0,05). ACT increase in 16.week and first year in allegic asthma group was greater comparing with increase in non-allergic asthma group (p<0,05).In second year this increase was similar (p>0,05). Decrease in exacerbation rate in 1. and 2. year in allergic asthma group and non-allergic asthma group was found similiar (p> 0,05).Add on omalizumab in compatible severe non-allergic asthma patients seems benefical therapy for current control and future risk for exacerbations.